Literature DB >> 35131845

Pancreatic Insufficiency in a Child with p.Gly542* and c.2657+5G>A Heterozygote CFTR: A Case Report.

Fernanda Dos Anjos1, Jonatha Wruck1, Thiago Inácio Teixeira do Carmo1, Victor Emanuel Miranda Soares1, Débora Tavares de Resende E Silva2, Margarete Dulce Bagatini3, Sarah Franco Vieira de Oliveira Maciel4.   

Abstract

Cystic fibrosis is a monogenic and autosomal recessive disease. It is caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator gene responsible for encoding the CFTR protein. Involvement of the gastrointestinal and respiratory systems is the main clinical manifestation. In this case, we report a heterozygous CFTR patient harboring class I (p.Gly542*) and class V (c.2657+5G>A) mutations. The importance of this case report lies in the clinical features because the patient, aged 3 years, presented with early exocrine pancreatic insufficiency, which can be considered atypical, as most individuals with this genotype are pancreatic sufficient or develop pancreatic insufficiency later in life. This report aims at presenting the tests requested that contributed to the patient's diagnosis, as well as at understanding the association between these mutations and their phenotypic presentation. Interpretation of the genotype-phenotype relationship represents a challenge, as genetic analysis alone is not sufficient to clearly predict severity of the disease. This is because the significant phenotypic heterogeneity existing among patients with the same genotype may exert socioeconomic and sociocultural influences, or by the action of CFTR modifiers, such as environmental and modifying genes, which can alter the protein's function and exert an impact on the individual's phenotype.
© 2022 Marshfield Clinic Health System.

Entities:  

Keywords:  CFTR heterozygous; Cystic Fibrosis; Exocrine pancreatic insufficiency; c.2657+5G>A; p.Gly542*

Mesh:

Substances:

Year:  2022        PMID: 35131845      PMCID: PMC9390849          DOI: 10.3121/cmr.2022.1618

Source DB:  PubMed          Journal:  Clin Med Res        ISSN: 1539-4182


  27 in total

1.  Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis.

Authors:  Chee Y Ooi; Ruslan Dorfman; Marco Cipolli; Tanja Gonska; Carlo Castellani; Katherine Keenan; Steven D Freedman; Julian Zielenski; Yves Berthiaume; Mary Corey; Susanne Schibli; Elizabeth Tullis; Peter R Durie
Journal:  Gastroenterology       Date:  2010-11-09       Impact factor: 22.682

2.  A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis.

Authors:  L E GIBSON; R E COOKE
Journal:  Pediatrics       Date:  1959-03       Impact factor: 7.124

3.  Immunoreactive Trypsinogen (IRT) as a Biomarker for Cystic Fibrosis: challenges in newborn dried blood spot screening.

Authors:  Bradford L Therrell; W Harry Hannon; Gary Hoffman; Jelili Ojodu; Philip M Farrell
Journal:  Mol Genet Metab       Date:  2012-02-28       Impact factor: 4.797

Review 4.  Genotype and phenotype in cystic fibrosis.

Authors:  J Zielenski
Journal:  Respiration       Date:  2000       Impact factor: 3.580

5.  The relevance of sweat testing for the diagnosis of cystic fibrosis in the genomic era.

Authors:  Avantika Mishra; Ronda Greaves; John Massie
Journal:  Clin Biochem Rev       Date:  2005-11

Review 6.  Pancreatic insufficiency in Cystic Fibrosis.

Authors:  Vikesh K Singh; Sarah Jane Schwarzenberg
Journal:  J Cyst Fibros       Date:  2017-11       Impact factor: 5.482

Review 7.  The future of cystic fibrosis care: a global perspective.

Authors:  Scott C Bell; Marcus A Mall; Hector Gutierrez; Milan Macek; Susan Madge; Jane C Davies; Pierre-Régis Burgel; Elizabeth Tullis; Claudio Castaños; Carlo Castellani; Catherine A Byrnes; Fiona Cathcart; Sanjay H Chotirmall; Rebecca Cosgriff; Irmgard Eichler; Isabelle Fajac; Christopher H Goss; Pavel Drevinek; Philip M Farrell; Anna M Gravelle; Trudy Havermans; Nicole Mayer-Hamblett; Nataliya Kashirskaya; Eitan Kerem; Joseph L Mathew; Edward F McKone; Lutz Naehrlich; Samya Z Nasr; Gabriela R Oates; Ciaran O'Neill; Ulrike Pypops; Karen S Raraigh; Steven M Rowe; Kevin W Southern; Sheila Sivam; Anne L Stephenson; Marco Zampoli; Felix Ratjen
Journal:  Lancet Respir Med       Date:  2019-09-27       Impact factor: 30.700

Review 8.  Transcriptional regulation of CFTR gene expression.

Authors:  Austin E Gillen; Ann Harris
Journal:  Front Biosci (Elite Ed)       Date:  2012-01-01

Review 9.  Role of inflammation and oxidative stress in tissue damage associated with cystic fibrosis: CAPE as a future therapeutic strategy.

Authors:  Victor Emanuel Miranda Soares; Thiago Inácio Teixeira do Carmo; Fernanda Dos Anjos; Jonatha Wruck; Sarah Franco Vieira de Oliveira Maciel; Margarete Dulce Bagatini; Débora Tavares de Resende E Silva
Journal:  Mol Cell Biochem       Date:  2021-09-16       Impact factor: 3.396

10.  Clinical and Genotypical Features of False-Negative Patients in 26 Years of Cystic Fibrosis Neonatal Screening in Tuscany, Italy.

Authors:  Giovanni Taccetti; Matteo Botti; Vito Terlizzi; Maria Chiara Cavicchi; Anna Silvia Neri; Valeria Galici; Gianfranco Mergni; Claudia Centrone; Diego G Peroni; Filippo Festini
Journal:  Diagnostics (Basel)       Date:  2020-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.